Dr. Katina Robison, MD | Providence, RI ...

Dr. Katina M. Robison

Claim this profile

Women and Infants Hospital

Studies Ovarian Cancer
Studies Cancer
14 reported clinical trials
29 drugs studied

Area of expertise

1Ovarian Cancer
Katina M. Robison has run 6 trials for Ovarian Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage III
2Cancer
Katina M. Robison has run 4 trials for Cancer. Some of their research focus areas include:
Stage I
Stage II
Stage IV

Affiliated Hospitals

Image of trial facility.
Women And Infants Hospital
Image of trial facility.
Women & Infants Hospital

Clinical Trials Katina M. Robison is currently running

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Image of trial facility.

Ipatasertib + Chemotherapy

for Cancer

This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2

More about Katina M. Robison

Clinical Trial Related7 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Katina M. Robison has experience with
  • Paclitaxel
  • Letrozole
  • Quality-of-Life Assessment
  • Questionnaire Administration
  • Selinexor
  • Matching Placebo For Selinexor

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Katina M. Robison specialize in?
Is Katina M. Robison currently recruiting for clinical trials?
Are there any treatments that Katina M. Robison has studied deeply?
What is the best way to schedule an appointment with Katina M. Robison?
What is the office address of Katina M. Robison?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security